Laflunimus

This classification denotes an immunosuppressant with the molecular formula C15H13F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 44EH625IUS, chemically known as (z)alpha-cyano-alpha(sup 4),alpha(sup 4),alpha(sup 4)-trifluoro-beta-hydroxycyclopropaneacrylo-3,4-xylide. but more generally known as laflunimus, which bears US NIH Compound Identifier 5745208. European Medicines Agency schedules Laflunimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08387MIG. The term LAFLUNIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). LAFLUNIMUS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule laflunimus under HS 29269095 and SITC 51484. As of Q4 2014, LAFLUNIMUS remains US FDA's Preferred Term for this commodity. Laflunimus bears US NLM identifiers UMLS ID C2825486 and NCI Concept Code C81163. SMILES: FC(F)(F)C1C(CC(NC(=C(\C(=O)C2CC2)C#N)\O)CC1)C.